SER100 in Isolated Systolic Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.

In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The PK/PD Study of SHR0532 Tablets in Healthy Subjects

NCT03645278

Hypertension

UNKNOWN PHASE1

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

NCT01911780

Hypertension

COMPLETED PHASE3

Low-dose Quadruple Combination Therapy in Patients With Hypertension

NCT05377203

Hypertension Arterial Hypertension

COMPLETED PHASE4

Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

NCT00160212

Hypertension

COMPLETED PHASE2

Essential Hypertension

NCT01264692

Essential Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Isolated Systolic Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SER100

SER100 10 mg s.c. twice daily

Group Type EXPERIMENTAL

SER100

Intervention Type DRUG

Placebo

Intervention Type DRUG

Placebo

Placebo administered s.c. twice daily

Group Type PLACEBO_COMPARATOR

SER100

Intervention Type DRUG

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SER100

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure \< 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
* Male or female
* Age 50-80 years (both inclusive) at screening
* Patients must be on stable doses with one or more antihypertensives
* BMI \<32 kg/m2
* Written informed consent

Exclusion Criteria

* Acute myocardial infarction in the last 6 months before screening
* Stroke in the last 6 months before screening
* Uncompensated heart failure (NYHA Class IV)
* Angina pectoris with an anticipated need for administration of short-acting nitrates
* Known, severe sleep apnoea
* Abnormal laboratory values (i.e. \> 2 x upper normal limit) at screening
* Subjects working night shifts (11 PM to 7 AM)
* Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
* Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
* Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance
* Pregnant or lactating women.
* Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No